Embecta Corp. EMBC
Institutional shares held
51.4 Million
162K
calls
61K
puts
Total value of holdings
$1.03B
$3.24M
calls
$1.22M
puts
Market Cap
$1.16B
57,836,500
Shares Out.
Institutional ownership
88.86%
# of Institutions
406
We take great care to ensure that the data presented and summarized in this overview for Embecta Corp. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding EMBC
View all-
Black Rock Inc. New York, NY9.19MShares$184 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7MShares$140 Million0.0% of portfolio
-
River Road Asset Management, LLC3.48MShares$69.7 Million0.69% of portfolio
-
American Century Companies Inc Kansas City, MO3.02MShares$60.5 Million0.03% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY2.73MShares$54.7 Million0.72% of portfolio
-
Donald Yacktman Yacktman Asset Management LP2.53MShares$50.6 Million0.39% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.41MShares$48.2 Million0.02% of portfolio
-
State Street Corp Boston, MA2.31MShares$46.3 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.39MShares$27.8 Million0.0% of portfolio
-
Rubric Capital Management LP New York, NY1.09MShares$21.8 Million0.43% of portfolio
Latest Institutional Activity in EMBC
Top Purchases
Top Sells
About EMBC
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.
Insider Transactions at EMBC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 02
2024
|
Anthony M. Roth Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,762
+50.0%
|
-
|
|
Nov 26
2024
|
Jacob Elguicze SVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
9,785
-5.42%
|
$176,130
$18.7 P/Share
|
|
Nov 26
2024
|
Jacob Elguicze SVP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
61,498
+25.4%
|
-
|
|
Nov 26
2024
|
Shaun Curtis SVP, Global Manuf./Sup. Chain |
SELL
Payment of exercise price or tax liability
|
Direct |
5,806
-8.64%
|
$104,508
$18.7 P/Share
|
|
Nov 26
2024
|
Shaun Curtis SVP, Global Manuf./Sup. Chain |
BUY
Grant, award, or other acquisition
|
Direct |
24,065
+26.37%
|
-
|
|
Nov 26
2024
|
Devdatt Kurdikar President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
48,956
-8.44%
|
$881,208
$18.7 P/Share
|
|
Nov 26
2024
|
Devdatt Kurdikar President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
187,166
+24.39%
|
-
|
|
Nov 26
2024
|
Jeffrey Z Mann SVP, GC, Head Corp. Dev., Secy |
SELL
Payment of exercise price or tax liability
|
Direct |
8,016
-5.32%
|
$144,288
$18.7 P/Share
|
|
Nov 26
2024
|
Jeffrey Z Mann SVP, GC, Head Corp. Dev., Secy |
BUY
Grant, award, or other acquisition
|
Direct |
50,803
+25.23%
|
-
|
|
Nov 26
2024
|
Jean Casner Chief Human Resources Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,281
-2.58%
|
$23,058
$18.7 P/Share
|
|
Nov 26
2024
|
Jean Casner Chief Human Resources Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,396
+32.06%
|
-
|
|
Aug 09
2024
|
Jean Casner Chief Human Resources Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
916
-3.4%
|
$13,740
$15.39 P/Share
|
|
May 10
2024
|
Jacob Elguicze SVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,013
-0.85%
|
$14,182
$14.24 P/Share
|
|
Apr 04
2024
|
Devdatt Kurdikar President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,535
-1.16%
|
$54,420
$12.78 P/Share
|
|
Feb 12
2024
|
David F Melcher Director |
BUY
Open market or private purchase
|
Direct |
2,000
+4.25%
|
$32,000
$16.25 P/Share
|
|
Feb 11
2024
|
Devdatt Kurdikar President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
17,165
-4.22%
|
$274,640
$16.26 P/Share
|
|
Feb 07
2024
|
Carrie L Anderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,455
+31.51%
|
-
|
|
Feb 07
2024
|
David Albritton Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,455
+31.51%
|
-
|
|
Feb 07
2024
|
David F Melcher Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,892
+14.9%
|
-
|
|
Feb 07
2024
|
Robert J. Hombach Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,455
+31.51%
|
-
|
Last 12 Months Summary
Buy / Acquisition
460K
Shares
From
15
Insiders
| Grant, award, or other acquisition | 458K shares |
|---|---|
| Open market or private purchase | 2K shares |
Sell / Disposition
97.5K
Shares
From
5
Insiders
| Payment of exercise price or tax liability | 97.5K shares |
|---|